A clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for approximately 5.5 million new cases of cancer worldwide per year.
Lead Underwriter
BofA Securities, Inc, Evercore Group L.L.C, Guggenheim Securities, LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC
